Enovis ENOV Prevention & Recovery — Research and development expense

Other segment segments

Reconstructive

$23.79M+23.3%

Similar metrics at other companies

BAXMedical Products & Therapies — Research and development expenses

$54M-8.5%

BDXMedical — Research and development expense

$130.75M+17.0%

OSISHealthcare Division — Research And Development Expense

$4.63M+7.7%

AVNSPM&R — Research and development expenses

-$1.3M-18.2%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

JNJInnovative Medicine — Research and development expense

$2.81B+10.4%

Other financials

Income statement

See full

Revenue$589.2M+5.4%

Gross profit$365.5M+10.0%

Operating income$6.5M+114%

Net income-$8.8M+84.3%

EPS (diluted)-$0.15+84.7%

Balance sheet

See full

Cash & equivalents$33.1M-13.9%

Total debt$1.4B-3.1%

Total equity$1.5B-43.6%

Total assets$3.8B-21.4%

Cash flow

See full

Operating cash flow$24.0M+1,601%

CapEx$52.8M+22.1%

Free cash flow-$28.9M+35.7%

Valuation

See full

Market cap$1.23B-28.4%

Enterprise value$2.55B-17.1%

P/S0.5×-0.3×

Profitability

See full

Gross margin60.5%+4.0pp

Operating margin-47%+18.6pp

Net margin-49.9%+24.1pp

FCF margin-3.1%-1.1pp

Returns & leverage

See full

Return on equity-55.5%-1,722pp

Debt / equity0.9×+0.4×

Current ratio2×-0.5×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Enovis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enovis's prevention & recovery — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Enovis's prevention & recovery — research and development expense?: Enovis (ENOV) reported prevention & recovery — research and development expense of $7.75M in Q1 2026.
What does prevention & recovery — research and development expense mean?: The total expenditure dedicated to the discovery, design, and clinical testing of new medical technologies and product enhancements within the Prevention & Recovery segment. This investment is critical for maintaining the segment's competitive edge and driving long-term innovation in patient outcomes.